Exclusive-US weighs allowing most pharma licensing deals with China, sources say
The US is weighing permission for most pharmaceutical licensing deals with China, according to sources cited by Investing.com. The proposal could ease a channel for cross-border drug partnerships, but its scope and timing remain unsettled.
The policy under consideration would allow most pharmaceutical licensing agreements involving China, according to sources cited by Investing.com. No final decision, implementation timetable or list of transactions covered was specified.
The proposal would represent a potentially less restrictive approach to pharma-related commercial ties between the US and China. Its practical effect would depend on the kinds of licenses covered and on any remaining controls affecting technology, data, investment or end-use.
US and Chinese pharmaceutical companies could be affected through licensing fees, development partnerships and rights to commercialize medicines in the other market. The mechanism is contractual: a broader permitted set of deals could expand the number of cross-border transactions that can proceed, while narrower rules would limit the benefit.
The report attributes the proposal to sources, and the policy has not been presented as a completed decision. The details of any exemptions, review process and enforcement conditions are therefore open.
The next concrete markers are a formal US policy announcement and any accompanying guidance defining which licensing agreements qualify. Company-specific read-through would require named deals or transaction disclosures after those rules are clarified.
The reported policy review is broadly supportive for cross-border pharma deal flow, but its unfinalized scope leaves the read mixed across the sector.
The immediate implication is a possible easing of a major transaction constraint, which could improve the path for US-China pharma licensing agreements. Because the proposal is attributed to sources and its scope is undefined, the commercial impact cannot yet be assigned to a specific company or revenue line.
A narrower policy, added review conditions or no formal change would remove the expected benefit to cross-border licensing activity.
CoverageSource: Investing.com · Published here FRI, SEP 18 · 1:01 PM ET · the only report in this recordHow this is decided →
STOCK PHOTO · PHIL EVENDENEarlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Allowing most licensing deals would reopen a broader route for pharma companies to earn fees and commercialize medicines through Chinese partners.
Limited bear case for the policy read: the proposal remains unfinalized, and unspecified restrictions could leave many commercially important transactions outside its scope.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →